Guilin Sanjin Pharmaceutical Co., Ltd. (SHE:002275)

Market Cap	8.29B +2.7%
Revenue (ttm)	2.08B -1.6%
Net Income	522.88M +28.1%
EPS	0.90 +30.2%
Shares Out	587.57M
PE Ratio	15.67
Forward PE	n/a
Dividend	0.55 (3.90%)
Ex-Dividend Date	Nov 19, 2025

Volume	2,200,900
Average Volume	2,325,604
Open	14.09
Previous Close	14.11
Day's Range	13.95 - 14.14
52-Week Range	12.90 - 17.38
Beta	0.34
RSI	42.09
Earnings Date	Apr 29, 2026

About SHE:002275

Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China and internationally. The company offers three gold particles, Guilin watermelon frost, watermelon frost lozenges, throat clearing spray, Naomaitai capsules, vertigo tablets, Xuanyunning granules, Gejie dingchuan capsule, compound panax notoginseng stomachache capsule, compound panax notoginseng stomach pain tablets, Sanqi xueshangning capsules, Sanqi xueshangning powder, compound luo han guo qing fei granule...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 2,567
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002275

Financial Performance

In 2024, SHE:002275's revenue was 2.19 billion, an increase of 1.03% compared to the previous year's 2.17 billion. Earnings were 521.53 million, an increase of 23.79%.